share_log

On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing

Benzinga ·  Dec 28, 2023 16:39

The Company and Boyle also entered into a consulting agreement, effective January 1, 2024, pursuant to which Boyle will continue providing strategic and advisory services to the company. The Consulting Agreement will continue for a period of six months.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment